EP1233963A2 - Nouvelles sulfonyloxazolamines - Google Patents

Nouvelles sulfonyloxazolamines

Info

Publication number
EP1233963A2
EP1233963A2 EP00990614A EP00990614A EP1233963A2 EP 1233963 A2 EP1233963 A2 EP 1233963A2 EP 00990614 A EP00990614 A EP 00990614A EP 00990614 A EP00990614 A EP 00990614A EP 1233963 A2 EP1233963 A2 EP 1233963A2
Authority
EP
European Patent Office
Prior art keywords
general formula
compound
hai
compounds according
solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00990614A
Other languages
German (de)
English (en)
Inventor
Rolf Gericke
Henning Böttcher
Michael Gassen
Hartmut Greiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of EP1233963A2 publication Critical patent/EP1233963A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the invention relates to sulfonyloxazolamines of the general formula I and their use as medicaments and a process for their preparation, the intermediates used in the production process and a process for the preparation of the intermediates.
  • the sulfonyloxazolamines according to the invention are compounds of the general formula I
  • Ri and R independently of one another H, -R ⁇ , C 3 -C 8 cycloalkyl, - (CH) n -R, - (CH 2 ) n O-R6, - (CH 2 ) n -NH 2 , - ( CH 2 ) n -NHR 6 , - (CH 2 ) -N (R 6 ) 2 , C 2 -C 6 alkenyl or optionally together form a mononuclear saturated heterocycle with one or two nitrogen, oxygen and / or sulfur atoms,
  • R 3 and Ri independently of one another are H, -R $, -CF, -NO 2 , -Hai, -OH, -OR ⁇ , -NH 2 , -NH-R ⁇ or -N (R 6 ) 2
  • R 5 represents a 5- or 6-membered, saturated or unsaturated heterocycle, with one or two nitrogen, oxygen and / or sulfur atoms, which may be replaced by -R ⁇ , -CF 3 , -NO 2 , -Hai, -OH, -OR * , -NH 2 , -NH-R ⁇ , or -N (R 6 ) is mono- or disubstituted, and
  • R ⁇ means Ci-C ö alkyl
  • R7 means phenyl substituted with R and / or R
  • n means 0 to 2
  • physiologically acceptable salts or solvates
  • the object of the invention was to find sulfonyloxazolamines with valuable properties. In particular, it was necessary to find pharmacologically active sulfonyloxazolamines.
  • the compounds of the formula I and their pharmacologically active salts with good tolerability, surprisingly have a selective affinity for 5-HT6 receptors, that is to say 5-HT6 receptor ligands. They have 5-HT6 antagonistic or 5-HT6 agonistic effects.
  • 5-HT6 receptors form a subfamily of 5-HT receptors.
  • the neurotransmitter 5-hydroxytryptamine (5-HT) also known as serotonin, is an important regulating neurotransmitter in the brain, the effects of which are supported by a family of receptors that currently contain 13 G protein-coupled receptors and an ion channel ,
  • the 5-HT6 receptors also belong to the group of G protein-coupled receptors.
  • the greatest density of serotonin 5-HT6 receptors in the brain is found in the olfactory tubercle, in the nucleus accumbens, in the striatum, in the dentate gyrus and in the CA1-3 regions of the hippocampus. These regions are particularly involved in psychiatric disorders such as schizophrenia or depression. It is also known from animal experiments that the administration of 5-HT6 antisense oligonucleotides causes a behavioral syndrome which corresponds to that of dopamine agonists. Furthermore, an overfunction of the dopaminergic neurotransmitter system in schizophrenia (dopamine hypothesis of schizophrenia) is confirmed pathophysiologically. However, dysfunction of the dopamine system in various forms of depression has also been demonstrated.
  • a large number of the established or newer therapeutic agents used to treat these psychiatric disorders in clinical practice also bind to the 5-HT6 receptor.
  • the atypical new roleptics e.g. clozapine
  • the tricyclic antidepressants e.g. amitriptyline
  • the 5-HT6 receptor is involved in psychiatric and neurological diseases such as preferably schizophrenia, depression and Alzheimer's.
  • the compounds of the formula I and their physiologically acceptable salts are therefore suitable as therapeutic active ingredients for diseases of the central nervous system.
  • the compounds of the formula I and their physiologically acceptable salts or solvates are particularly suitable for the treatment of psychoses, schizophrenia, manic depression (BL Roth et al., J Pharmacol. Exp. Ther. 1994, 268, 1403-1410), depression (DR Sibley et al., Mol. Pharmacol. 1993, 43, 320-327), neurological disorders (A. Bourson et al, J Pharmacol. Exp. Ther.
  • Solvates of the compounds of the formula I are understood to mean the addition of “inert” solvent molecules to the compounds of the formula I which are formed on account of their mutual attraction. Solvates are, for example, mono- or dihydrates or alcoholates.
  • R 3 and j are preferably independently of one another methyl, methoxy, chlorine and bromine or hydrogen.
  • R3 is phenyl, o- or p-methylphenyl, o- or p-chlorophenyl, p-bromophenyl, p-methoxyphenyl or 2,4-dichlorophenyl.
  • R and R together can also form a mononuclear saturated heterocycle having 1 to 2 N, O and / or S atoms.
  • This heterocycle is preferably tetrahydro-2- or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro- 1-, -2- or 4-imidazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1-, 2-, 3- or 4-piperidinyl, 1-, 2-, 3- or 4-perhydro -azepinyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1, 4-dioxanyl, l, 3-dioxan-2-, -4- or -5-yl , Hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimidinyl or 1-, 2- or 3-pipe
  • R 3 and / or R 4 are preferably H.
  • R preferably represents 2-furyl, 2-thienyl or 3- or 4-pyridyl.
  • R ⁇ is linear or branched and has 1 to 6, preferably 1, 2, 3 or 4 carbon atoms.
  • R ⁇ preferably means methyl, furthermore ethyl, propyl, butyl, isobutyl, sec-butyl or tert-butyl, further also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl or hexyl. Methyl is particularly preferred.
  • Alkenyl is preferably allyl, 2- or 3-butenyl, isobutenyl, sec-butenyl, further preferred is 4-pentenyl, isopentyl or 5-hexenyl. Allyl is particularly preferred for alkenyl.
  • a base of the general formula I can be converted into the associated acid addition salt using an acid, for example by reacting equivalent amounts of the base and the acid in an inert solvent such as ethanol and subsequent evaporation.
  • acids that provide physiologically acceptable salts are suitable for this implementation.
  • So inorganic acids can be used, e.g. Sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, furthermore organic acids, especially aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, e.g.
  • Formic acid acetic acid, propionic acid, pivalic acid, diethyl acetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methanoic acid, toluenesulfonic acid, toluenesulfonic acid, toluenesulfonic acid, toluenesulfonic acid, toluenesulfonic acid, toluenesulfonic acid, toluenesulfonic acid, toluenesulfonic acid, toluenesulfonic acid, toluenesulfonic acid, toluenesulfonic acid, toluenesulfonic acid, toluenesulfonic acid, toluenesulfonic acid,
  • Another object of the invention is the use of the compounds of the general formula I and their physiologically acceptable salts and solvates for the production of medicaments, in particular for the production of anticonvulsants, nootropics, anti-inflammatories, neuro- and cerebroprotectives, and of medicaments for the treatment of Central nervous system disorders, in particular for the treatment of schizophrenia, depression, pathological anxiety, epilepsy, pathological memory disorders such as Alzheimer's disease, neurological disorders, amyotrophic lateral sclerosis, Huntigton's disease, disorders of the gastrointestinal tract, irritable stomach, irritable bowel syndrome, bulimia, nervous anorexia , Compulsive acts (obsessive-compulsive disorder, OCD), premenstrual syndrome, migraines, pharmacological dependencies, sleep disorders and / or for the treatment of head and spine injuries.
  • Compulsive acts obsessive-compulsive disorder, OCD
  • premenstrual syndrome migraines, pharmacological dependencies, sleep
  • the substances according to the invention are generally administered in the dosage preferably between about 1 and 500 mg, in particular between 5 and 100 mg, per dosage unit.
  • the daily dosage is preferably between about 0.02 and 10 mg kg body weight.
  • the specific dose for each patient depends on a wide variety of factors, for example on the effectiveness of the particular compound used, on the age, body weight, general health, sex, on the diet, on the time and route of administration, on the rate of excretion and combination of drugs and severity of the respective disease to which the therapy applies. Oral application is preferred.
  • the compounds of the general formula I can also be used as pesticide.
  • Another object of the invention is a pharmaceutical preparation containing at least one compound according to general formula I and its physiologically acceptable salts and solvates, and optionally carriers and / or auxiliaries.
  • Suitable carriers are organic or inorganic substances which are suitable for enteral (e.g. oral), parenteral or topical application and do not react with the new compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly.
  • Tablets, pills, dragees, capsules, powders, granules, syrups, juices or drops are used for oral use, suppositories for rectal use, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants for topical use for parenteral use Ointments, creams or powder.
  • the new compounds can also be lyophilized and the lyophilizates obtained used, for example, for the production of injectables.
  • the specified preparations can be sterilized and / or auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, coloring, flavoring and / or one or more further active substances contain, for example, one or more vitamins.
  • auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, coloring, flavoring and / or one or more further active substances contain, for example, one or more vitamins.
  • the therapeutic agents of formula I or their physiologically acceptable salts or solvates, the use of compounds of formula I or their physiologically acceptable salts or solvates as therapeutic agents or the preparation of a pharmaceutical preparation for the treatment of diseases of the central nervous system Compounds of formula I the more preferred, the more radicals have one of the preferred or particularly preferred meanings given above.
  • Another object of the invention is the preparation of compounds of general formula I, wherein R 2 R 2 NH are reacted with compounds of general formula II or III.
  • R 3 and t independently of one another stand for H, -R ⁇ , -CF 3 , -NO 2 , -Hai, -OH, -OR ⁇ , -NH, - NH-Re or N (Re) 2 ,
  • R 5 represents a 5- or 6-membered, saturated or unsaturated heterocycle, with one or two nitrogen, oxygen and / or sulfur atoms, which may be replaced by -R ⁇ , -CF 3 , -NO 2 , -Hai, -OH, -O -Re, -NH 2 , -NH-R ⁇ , or N (R ⁇ ) is mono- or disubstituted, and ⁇ C ⁇ -C 6 alkyl.
  • R 3 and R 4 independently of one another represent H, -R ⁇ , -CF 3 , -NO 2 , -Hai, -OH, -OR 6 , -NH, - NH-Re or N (R 6 ) 2 ,
  • Rs represents a 5- or 6-membered, saturated or unsaturated heterocycle, with one or two nitrogen, oxygen and / or sulfur atoms, which may be replaced by -R «, -CF 3 , -NO 2 , -Hai, -OH, -O -Re, -NH 2 , -NH-R ö , or N (R ⁇ ) 2 is mono- or disubstituted, and
  • R5 C 1 -C 6 alkyl.
  • the compounds of general formula I can be synthesized according to the following synthetic scheme (reference is made to VA Chervonyi et al., Ukr. Khim. Zh. (Russ. Ed.) 1991, 57 (4), 415-418; VA Chervonyi et al., Zh. Org. Khim. 1988, 24 (2), 453-4 according to VA Chervonyi et al., J Org. Chem. USSR (English transl.) 1988, 24, 401; F. Weygand et al. Chem. Ber. 1966, 99, 1944-1956; H. Böhme et al. Arch Pharmaz., 1961, 294, 307-311; AN Meldrum and GM Vad Jndian Chem. Soc. 1936, 13, 117-118; DZ Barczynski and Z. Eckstein Przem Chem., 1978, 57, 176-177; F. Kasper and H. Böttger Z Chem. 1987, 27, 710-71):
  • the invention thus also relates to a process for the preparation of a compound of the general formula (II), characterized in that a) R 5 -CONH- 2 is added to chloral, b) the product from a) is chlorinated with thionyl chloride, c ) the product from b) with an alkali metal salt of a compound of the general formula (IV)
  • R 3 (IV) is reacted, where R 3 and R 4 have the meanings given above and Me + is an alkali metal cation, preferably Na + .
  • N- (l-Phenylsulfonyl-2,2-dichloro-vinyl) -nicotinamide (0.4 g, 1.120 mmol) is dissolved in tetrahydrofiiran, methylamine (2.607 ml, 2M in tetrahydrofiirane, 4.480 mmol) is added and the mixture is overnight at room temperature touched. The resulting precipitate was filtered off with suction and discarded, the mother liquor was concentrated on a rotary evaporator and the residue was crystallized with a small amount of isopropanol, filtered off with suction and dried in air. Mp: 191-193 ° C, decomposes
  • Example 4-40 The following compounds were prepared analogously.
  • Ph phenyl decomp .: decomposition
  • the substances to be tested were dissolved in DMSO at a concentration of 1 mM and diluted to the desired concentrations (0.1 nM to 10 ⁇ M) with test buffer (20 mM HEPES, 0.1% ascorbic acid, adjusted to pH 7.4 with NaOH).
  • the filters were washed 3 times with 3 ml of test buffer, the filters were transferred to minivials and, after adding Ultima Gold (Packard, Frankfurt), the radioactivity was determined in a liquid scintillation counter.
  • the evaluation and IC 50 determination was carried out using our own programs in RS1 (BBN software cooperation).
  • the compounds of formula I have a selective affinity for 5-HT6 receptors with an inhibition constant IC 50 of less than 4 nmol / 1.
  • a solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water with 2N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized under sterile conditions and sealed sterile. Each injection jar contains 5 mg of active ingredient.
  • a mixture of 20 g of an active ingredient of the formula I is melted with 100 g of soy lecithin and 1400 g of cocoa butter, poured into molds and allowed to cool. Each suppository contains 20 mg of active ingredient.
  • Example 44 Solution A solution is prepared from 1 g of an active ingredient of the formula I, 9.38 g of NaH 2 PO 4 -2 HO, 28.48 g of Na 2 HPO 4 T2 H 2 O and 0.1 g of benzalkonium chloride in 940 ml of double distillation Water. The pH is adjusted to 6.8, and the solution is made up to 1 1 and sterilized by irradiation. This solution can be used in the form of eye drops.
  • a mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1, 2 kg of potato starch, 0.2 g of talc and 0.1 kg of magnesium stearate is compressed into tablets in a conventional manner such that each tablet contains 10 mg of active ingredient.
  • Example E tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and colorant.
  • Example 48 Capsules 2 kg of active ingredient of the formula I are filled into hard gelatin capsules in a conventional manner, so that each capsule contains 20 mg of the active ingredient.
  • a solution of 1 kg of active ingredient of the formula I in 60 ml of double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed sterile. Each ampoule contains 10 mg of active ingredient.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne des composés de la formule générale (I) ainsi que leurs sels ou solvats acceptables sur le plan physiologique. Dans ladite formule (I), R1 et R2 représentent indépendamment l'un de l'autre H, -R6, cycloalkyle C3-C8, -(CH2)n-R7, -(CH2)n-O-R6, -(CH2)n-NH2, -(CH2)n-NHR6, -(CH2)-N(R6)2, alcényle C2-C6 ou éventuellement forment ensemble un hétérocycle saturé ayant un noyau avec un ou deux atomes d'azote, d'hydrogène et/ou de soufre; R3 et R4 représentent indépendamment l'un de l'autre H, -R6, -CF3, -NO2, -Hal, -OH, -O-R6, -NH2, -NH-R6, ou -N(R6)2; R5 représente un hétérocycle saturé ou insaturé à 5 ou 6 chaînons avec un ou deux atomes d'azote, d'hydrogène et/ou de soufre, hétérocycle éventuellement monosubstitué ou disubstitué par -R6, -CF3, -NO2, -Hal, -OH, -O-R6, -NH2, -NH-R6, ou -N(R6)2; R6 représente alkyle C1-C6, R7 avec R3 et/ou R4 représente phényle substitué ; et n représente 0 à 2. La présente invention concerne également l'utilisation des composés de la formule générale (I) comme médicaments.
EP00990614A 1999-11-25 2000-11-24 Nouvelles sulfonyloxazolamines Withdrawn EP1233963A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19956791A DE19956791A1 (de) 1999-11-25 1999-11-25 Neue Sulfonyloxazolamine
DE19956791 1999-11-25
PCT/EP2000/011734 WO2001038316A2 (fr) 1999-11-25 2000-11-24 Nouvelles sulfonyloxazolamines

Publications (1)

Publication Number Publication Date
EP1233963A2 true EP1233963A2 (fr) 2002-08-28

Family

ID=7930321

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00990614A Withdrawn EP1233963A2 (fr) 1999-11-25 2000-11-24 Nouvelles sulfonyloxazolamines

Country Status (18)

Country Link
US (1) US6737426B1 (fr)
EP (1) EP1233963A2 (fr)
JP (1) JP2003514902A (fr)
KR (1) KR20020058020A (fr)
CN (1) CN1423649A (fr)
AR (1) AR026589A1 (fr)
AU (1) AU3004201A (fr)
BR (1) BR0015814A (fr)
CA (1) CA2389679A1 (fr)
CZ (1) CZ20021687A3 (fr)
DE (1) DE19956791A1 (fr)
HU (1) HUP0204149A3 (fr)
MX (1) MXPA02005092A (fr)
NO (1) NO20022455D0 (fr)
PL (1) PL355152A1 (fr)
SK (1) SK6942002A3 (fr)
WO (1) WO2001038316A2 (fr)
ZA (1) ZA200203365B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129940A1 (de) * 2001-06-13 2002-12-19 Merck Patent Gmbh Sulfonyloxazolamine als therapeutische Wirkstoffe
WO2008061248A2 (fr) * 2006-11-16 2008-05-22 The Regents Of The University Of California Inhibiteurs à composé sulfoxyoxazole de transporteurs d'urée
DE602007012683D1 (de) * 2007-07-19 2011-04-07 Esteve Labor Dr Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente
RU2443697C1 (ru) * 2010-12-21 2012-02-27 Александр Васильевич Иващенко Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения
KR102533605B1 (ko) * 2018-01-10 2023-05-17 주식회사 라이조테크 신규한 페닐설포닐 옥사졸 유도체 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0930302B1 (fr) 1998-01-16 2003-04-02 F.Hoffmann-La Roche Ag Dérivés de benzosulfone
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
DE19858593A1 (de) 1998-12-18 2000-06-21 Merck Patent Gmbh Sulfonyloxazolamine als therapeutische Wirkstoffe

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0138316A2 *

Also Published As

Publication number Publication date
ZA200203365B (en) 2003-10-07
CZ20021687A3 (cs) 2002-08-14
US6737426B1 (en) 2004-05-18
DE19956791A1 (de) 2001-05-31
BR0015814A (pt) 2002-07-23
SK6942002A3 (en) 2002-12-03
PL355152A1 (en) 2004-04-05
HUP0204149A3 (en) 2005-04-28
NO20022455L (no) 2002-05-24
NO20022455D0 (no) 2002-05-24
CN1423649A (zh) 2003-06-11
CA2389679A1 (fr) 2001-05-31
MXPA02005092A (es) 2002-11-07
WO2001038316A2 (fr) 2001-05-31
WO2001038316A3 (fr) 2001-10-18
AR026589A1 (es) 2003-02-19
KR20020058020A (ko) 2002-07-12
JP2003514902A (ja) 2003-04-22
HUP0204149A2 (hu) 2003-04-28
AU3004201A (en) 2001-06-04

Similar Documents

Publication Publication Date Title
DE69524528T2 (de) ZNS wirksames (R)-(-)-2-[5-(4-Fluorophenyl)-3-pyridylmethylaminomethyl]chroman
DE69127260T2 (de) Therapeutische heterocyclische verbindungen
DE3884563T2 (de) Aminomethyl-oxo-oxazolidinyl-ethenylbenzen-Derivate, nützlich als antibakterielles Mittel.
DE69615376T2 (de) Piperazin-derivate als heilmittel
EP1198453B1 (fr) Derives de n-(indolcarbonyl-)piperazine
EP0736525B1 (fr) Benzonitriles comme 5-HT agonistes et antagonistes
DE4302051A1 (de) 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE102004008141A1 (de) Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren
DE10210779A1 (de) Cyclische Amide
EP1140875A1 (fr) Sulfonyloxazolamines en tant que principes actifs therapeutiques
DE10315570A1 (de) Triazolderivate
EP1611094B1 (fr) Composes pyrazole
AT396362B (de) 5,5-dimethyl-3-phenylvinyl-1-aminoalkoxy-iminocyclohex-2-enderivate
EP1233963A2 (fr) Nouvelles sulfonyloxazolamines
EP1228041B1 (fr) Derives indoliques et leur utilisation comme ligands 5ht2a
DE10315569A1 (de) Substituierte Pyrazolverbindungen
EP0763535B1 (fr) Dérivés de pipéridinylméthyloxazolidin-2-one, leur préparation et leur utilisation comme composés pharmacologiques actifs sur le système nerveux central
DE10129940A1 (de) Sulfonyloxazolamine als therapeutische Wirkstoffe
DE69107874T2 (de) Imidazolderivate und diese Imidazolderivate als Wirkstoffe enthaltende Antiepileptika.
EP0000693A1 (fr) Dérivés d'aminophénoxyméthyl-2-morpholine, procédé pour leur préparation et médicaments les contenant
DE69905191T2 (de) Kondensierte pyridazinonverbindungen
EP1572685B1 (fr) Benzodioxepines substituees
EP0158083A2 (fr) Médicaments
DE3850304T2 (de) 3-Arylcarbamoyl-5-aminomethyl-oxazolidine sowie deren Salz mit pharmakologisch verträglichen Säuren.
DD226881A5 (de) Verfahren zur herstellung von pyrimidonverbindungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020604

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT PAYMENT 20020604;LV PAYMENT 20020604;MK;RO PAYMENT 20020604;SI PAYMENT 20020604

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BOETTCHER, HENNING

Inventor name: GERICKE, ROLF

Inventor name: GREINER, HARTMUT

Inventor name: GASSEN, MICHAEL

17Q First examination report despatched

Effective date: 20040602

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041013